FDA Approval Alert: The Need-to-Know | Fruquintinib for Previously Treated Metastatic Colorectal Cancer

In November 2023, the FDA approved fruquintinib for patients with previously treated metastatic colorectal cancer based on results from the phase 3 FRESCO-2 trial.

Experts Discuss Impact of Fruquintinib Approval in Metastatic CRC
Experts Discuss Impact of Fruquintinib Approval in Metastatic CRC
Video
Nov 10, 2023 9:00 PM
Arvind N. Dasari, MD, lead investigator of the FRESCO-2 trial, spoke about the recent approval of fruquintinib for patients with previously treated metastatic colorectal cancer.
Results from the phase 3 FRESCO-2 trial support the approval of fruquintinib for patients with previously treated metastatic colorectal cancer.
FDA Approves Fruquintinib in Previously Treated Metastatic CRC
Article
Nov 8, 2023 11:31 PM
Results from the phase 3 FRESCO-2 trial support the approval of fruquintinib for patients with previously treated metastatic colorectal cancer.
Fruquintinib in the FRESCO-2 Trial
Fruquintinib in the FRESCO-2 Trial
Article
Sep 20, 2023 2:00 PM
Arvind N. Dasari, MD, and Cathy Eng, MD, gave an overview on the use of fruquintinib in colorectal cancer.